Haemophilia is the most common X-linked condition, affecting 1 in 5 000 and 1 in 25 000 live male births for haemophilia A
and B, respectively.
occurs in about one in 5,000 male births annually, and more rarely in females.
The most common type of haemophilia is called haemophilia A
and is a result of insufficient clotting factor VIII (factor eight).
Roche announced that the European Commission has approved Hemlibra for routine prophylaxis of bleeding episodes in people with severe haemophilia A
without factor VIII inhibitors.
Keywords: FVIII, FVIII alloantibodies, Haemophilia A
, Immune tolerance, Inhibitors, Risk factors.
The disease is categorised as haemophilia A
and B and can be classified as mild, moderate, or severe.
(factor VIII deficiency) and haemophilia B (factor IX deficiency) are the most common and serious congenital coagulation factor deficiencies.
Lloyd, "A protocol for the dental management of von Willebrand's disease, haemophilia A
and haemophilia B," Australian Dental Journal, vol.
Negrier, "Spontaneous proximal deep vein thrombosis in a patient with severe haemophilia A
," Blood Coagulation and Fibrinolysis, vol.
Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life and is the first haemophilia A
treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.
is the most common inherited bleeding disorder and affects all population groups.